Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for ...

Copenhagen, Denmark Wednesday, July 23, 2025, 10:00 Hrs [IST] ...

Chikungunya virus disease, a debilitating mosquito-borne (Aedes spp) illness caused by an alphavirus, chikungunya virus, is usually endemic in regions with tropical climates.1 Since the beginning of ...

Accelerated assessment allows for a shorter review period with EMA.Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024. COPENHAGEN ...

As for Bavarian Nordic, the vaccine specialist is differentiating itself from rival Valneva not only when it comes to PRV sale prices. In May, the FDA and the CDC recommended a pause in the use of ...

Bavarian Nordic has secured a DKK 200 million+ vaccine contract in Europe, bringing total public‑preparedness deals to over ...

With the U.S. FDA’s approval of Vimkunya, Bavarian Nordic A/S is now in the chikungunya virus infection mix along with Valneva SE’s Ixchiq. A single-dose, adjuvanted virus-like particle-based vaccine ...

Bavarian Nordic was awarded the PRV in February 2025, following the approval by the U.S. Food and Drug Administration of the chikungunya vaccine, VIMKUNYA™ for ...

Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women, as well as infants aged under two years. The first infants have been ...

It was only in February 2024 that Valneva monetized a PRV obtained from the FDA approval of the U.S.’s first approved chikungunya vaccine, Ixchiq, for $103 million.

Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company's application for licensure of the single-dose, virus-like ...